Mestinon contains pyridostigmine bromide and is a prescription treatment for people with myasthenia gravis. It may improve voluntary muscle strength by helping nerve signals remain available at the neuromuscular junction for longer, and the amount taken at each intake is set individually rather than fixed for everyone.
Myasthenia gravis disrupts communication between nerves and muscles. This can cause weakness that becomes more noticeable with activity and improves after rest. Mestinon is prescription treatment, and the amount per intake is set individually rather than being one fixed number for every person.
Pyridostigmine may improve weakness affecting the eyes, face, arms, legs, speech, swallowing, and breathing muscles. The response varies according to disease severity, daily activity, kidney function, other treatments, and the timing of each dose.
Worsening swallowing, slurred speech, severe weakness, or shortness of breath requires urgent medical assessment. These symptoms can reflect progression of myasthenia gravis or excessive cholinergic activity, and the two situations need different treatment.
Mestinon is used under prescription supervision. A prescriber usually adjusts the schedule around the times when weakness is most troublesome, such as early morning, meals, or periods of physical activity.
Health Canada product information describes pyridostigmine bromide as treatment that must be individualised according to clinical response and tolerability [1].
The prescribed amount per intake is set individually for each person rather than being one fixed amount. It may depend on the degree of muscle weakness, symptom timing, response to treatment, age, kidney function, and the formulation selected by the prescriber.
For the tablet presentation:
The tablet presentation is one available strength, not a standard regimen for every patient. Some people need doses spaced across the day, while others require a schedule built around meals, waking hours, or predictable periods of weakness.
Food may affect gastrointestinal tolerability. A person who develops cramping or diarrhoea soon after taking a tablet should record the timing, food intake, and symptoms rather than making a sudden dose change.
Kidney function matters because pyridostigmine is substantially cleared through the kidneys. Reduced clearance can increase exposure and may require a different schedule.
A missed dose should not usually be replaced with two tablets together. The next step depends on how close the missed dose is to the next scheduled intake and on the individual prescription.
Repeated missed doses can make weakness appear to be worsening. Repeated extra doses can increase cholinergic effects. Contact the prescribing team promptly when missed doses happen often or when the schedule no longer matches the daily pattern of weakness.
Mestinon contains pyridostigmine bromide. The 60 mg presentation is an oral tablet containing 60 mg of pyridostigmine bromide, as identified by the product presentation.
| Pharmaceutical fact | Mestinon |
|---|---|
| Active ingredient and class | Pyridostigmine bromide; reversible acetylcholinesterase inhibitor |
| Tablet presentation | 60 mg oral tablet |
| Treatment role | Supports nerve-to-muscle signalling in myasthenia gravis |
Acetylcholinesterase is the enzyme that breaks down acetylcholine, a chemical messenger released by nerves. Pyridostigmine slows this breakdown, allowing acetylcholine to remain active for longer where the nerve meets the muscle.
The tablet improves communication between nerves and muscles. It does not directly build muscle tissue or correct the autoimmune process behind myasthenia gravis.
A nerve signal reaches the neuromuscular junction and releases acetylcholine. Acetylcholine then binds to receptors on the muscle, helping the muscle contract. Acetylcholinesterase normally removes acetylcholine soon afterward.
Pyridostigmine inhibits this enzyme reversibly. More acetylcholine remains available for the muscle receptors, which can improve the reliability of voluntary contraction.
The process can be understood in five steps:
This mechanism explains both the benefit and the adverse effects. Too little cholinergic activity may leave weakness uncontrolled. Too much can cause abdominal cramps, diarrhoea, sweating, salivation, twitching, slow heart rate, or worsening weakness.
The U.S. Food and Drug Administration describes pyridostigmine as an acetylcholinesterase inhibitor that increases acetylcholine availability at cholinergic junctions [2].
Pyridostigmine bromide, the active ingredient of Mestinon, is a reversible cholinesterase inhibitor used mainly to improve voluntary muscle strength in people with myasthenia gravis. Mestinon 60 mg tablets help nerve signals remain available at the neuromuscular junction for longer, supporting movement, swallowing, and other muscle functions. The medicine controls symptoms but does not remove the autoimmune cause of myasthenia gravis.
Pyridostigmine may improve weakness affecting the eyes, face, arms, legs, speech, swallowing, and breathing muscles.
Several avoidable patterns can make Mestinon appear ineffective or poorly tolerated:
Keep doses consistent. Record the time of each tablet, the timing of weakness, meals, physical activity, and adverse effects. This creates a practical picture of how long each dose helps and whether symptoms follow a predictable pattern.
One detail patients often overlook is the difference between muscle weakness and fatigue. Myasthenia gravis weakness may worsen with repeated use and improve with rest, while general fatigue can have several causes. The distinction helps the clinician decide whether pyridostigmine adjustment is appropriate.
Another useful habit is to bring the actual medication list to every appointment, including occasional antihistamines, sleep products, supplements, and medicines used for colds. Anaesthesia teams also need this information before surgery.
A confirmed allergy to pyridostigmine, pyridostigmine bromide, or an excipient is a reason to avoid treatment. Mechanical obstruction of the gastrointestinal tract or urinary tract is also a contraindication because increased cholinergic activity can worsen obstruction.
This treatment is not for you without specific prescriber review if you have mechanical bowel or urinary obstruction, significant bradycardia, a known pyridostigmine allergy, or unexplained severe breathing weakness.
Mestinon can cause cholinergic effects because acetylcholine remains active for longer. Commonly reported problems include abdominal cramps, diarrhoea, nausea, increased salivation, sweating, urinary frequency, muscle twitching, and headache.
Mild digestive symptoms can be inconvenient without being dangerous. Persistent or severe symptoms still deserve review because they may indicate that the dose or timing needs adjustment.
Possible effects include:
Urgent assessment is required for marked weakness, difficulty breathing, inability to swallow, fainting, very slow heartbeat, heavy secretions, or rapidly worsening symptoms.
A cholinergic crisis results from excessive cholinergic activity and can produce weakness that resembles a myasthenic crisis. The distinction cannot be made reliably from symptoms alone. Do not take extra tablets to treat sudden severe weakness unless an emergency clinician gives that instruction.
Mestinon contains pyridostigmine, while neostigmine is a different cholinesterase inhibitor. Both increase acetylcholine availability, but their clinical roles and routes of administration differ.
| Feature | Mestinon | Neostigmine |
|---|---|---|
| Active substance and role | Pyridostigmine; commonly used orally for ongoing myasthenia gravis symptom control | Neostigmine; commonly used in supervised clinical or perioperative care |
| Administration | Oral tablet presentation | Often administered in a clinical setting by a selected route |
| Interchangeability | Individual prescription schedule | Requires separate dosing and monitoring decisions |
Neostigmine may be used by clinicians when rapid, supervised cholinesterase inhibition is required, including selected perioperative situations. Mestinon 60 mg tablets are used for ongoing oral symptom management when prescribed for that purpose.
The two medicines are not interchangeable by tablet count. A change from one to the other requires a new clinical plan.
Clinicians usually judge Mestinon by function, not by a single strength score. Useful signs include improved chewing, speech, eyelid control, walking endurance, arm movement, or ability to complete daily activities.
Prescribers also watch for the opposite pattern: cramping, diarrhoea, sweating, excessive saliva, twitching, slow pulse, and weakness soon after dosing. More tablets are not automatically better. The best schedule is the one that supports function without producing excessive cholinergic activity.
In clinical practice, symptom timing often provides the clearest information. A diary showing weakness before a dose, benefit afterward, and digestive symptoms later can help the prescriber adjust timing more safely than memory alone.
International consensus guidance recognises symptomatic treatment as one part of myasthenia gravis care, alongside assessment of disease activity and other immune-directed approaches [3].
Mechanical obstruction of the bowel or urinary tract is a major condition that rules out Mestinon because cholinergic stimulation can worsen the obstruction. A known allergy to pyridostigmine bromide or an ingredient is another reason not to use it. Health Canada information from 2025 also identifies caution around bradycardia and respiratory disease. Severe breathing or swallowing weakness needs urgent assessment rather than an extra dose. The prescriber should also review any new or rapidly worsening weakness.
The best timing follows the individual pattern of weakness and the prescribed schedule. Some people need coverage around waking, meals, or predictable activity, while others require evenly spaced doses. Health Canada guidance available in 2025 supports individualising pyridostigmine use according to symptoms and response. Take doses at consistent times and record when benefit or adverse effects occur.
Persistent weakness should prompt review of the schedule, formulation, kidney function, adherence, and the possibility that the symptoms have another cause. Do not keep increasing tablets independently because excessive cholinergic activity can also produce weakness. The U.S. Food and Drug Administration prescribing information from 2023 supports clinical reassessment when response is inadequate or tolerability changes. Breathing or swallowing problems require urgent care.
Alcohol may worsen dizziness, impaired coordination, or fatigue, which can make muscle weakness harder to judge. It may also make it more difficult to recognise early breathing or swallowing problems. Health Canada advice from 2025 does not make alcohol a universal substitute for medication review; the practical concern is the combined effect on alertness and function. Avoid alcohol when symptoms are unstable or when a clinician has advised against it.
The duration varies between people and depends on the formulation, kidney function, disease pattern, and the prescribed amount. A 60 mg tablet should not be treated as having one guaranteed duration for every patient. A 2016 review of myasthenia gravis in the New England Journal of Medicine describes pyridostigmine response as dependent on individual pharmacokinetic and clinical factors. A symptom diary can show when benefit begins to fade.
Discuss asthma, slow heart rate, fainting, peptic ulcer disease, kidney impairment, pregnancy, breastfeeding, and previous bowel or urinary obstruction. Provide every prescription medicine, supplement, over-the-counter product, and planned surgery. The EMA product information available in 2025 highlights the relevance of renal function and interactions affecting neuromuscular transmission. These details help determine whether the 60 mg tablet and schedule are appropriate.
Do not automatically take two tablets together after missing one. The correct action depends on how close the missed dose is to the next scheduled intake and on the individual prescription. Health Canada clinical information from 2025 supports avoiding unsupervised dose changes with pyridostigmine. If missed doses are frequent, or weakness becomes marked, contact the prescribing team promptly.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Mestinon is supplied here as 60 mg oral tablets. The product presentation is intended for swallowing, not for crushing, chewing, or changing into another route of administration unless a prescriber or pharmacist has specifically directed that approach.
Formulation differences matter. Regular tablets and modified-release pyridostigmine products can have different timing and dosing schedules, so they should not be substituted tablet-for-tablet without clinical direction.
| Product presentation | Strength | Clinical handling |
|---|---|---|
| Mestinon oral tablet | 60 mg | Use according to the individual prescription |
| Pyridostigmine tablet | 60 mg | Do not assume interchangeability with modified-release forms |
Approved presentations can vary by country. The prescriber should know which formulation is being used before changing the schedule.
Ian Z., 63 - Barrie, took the prescribed Mestinon 60 mg tablet schedule for several weeks. He noticed that chewing and speaking became easier during the part of the day when weakness had previously been most troublesome. The improvement was practical rather than dramatic, and he felt satisfied that ordinary meals required less effort.
Paul, 41 - St. John's, used Mestinon 60 mg tablets for several weeks but did not obtain the improvement he expected. He developed loose stools and abdominal cramping after some doses, and the combination of limited benefit and digestive symptoms led him to stop after discussing it with his doctor.
Gary, 66 - Montreal, used the 60 mg tablets according to an individually adjusted schedule. Within the first month, he found walking and lifting light household items easier at predictable times of day. He appreciated being able to plan activities around the period when the tablets helped most.
